Welcome to LookChem.com Sign In|Join Free

CAS

  • or

71-68-1

Post Buying Request

71-68-1 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

71-68-1 Usage

Chemical Properties

White Solid

Uses

Analgesic (narcotic). Preparation by electrolytic reduction of Morphine. Controlled substance (opiate).

Biochem/physiol Actions

Narcotic opiate analgesic; μ opioid receptor agonist.

Clinical Use

Hydromorphone is a potent μ agonist (eight times greater than morphine) that is used to treat severe pain. It is available in intramuscular, intravenous, subcutaneous, oral, and rectal dosage forms. Like all strong μ agonists, hydromorphone is addicting and is a Schedule II drug. Hydromorphone has an oral:parenteral potency ratio of 5:1. The plasma half-lives after parenteral and oral dosage are 2.5 and 4 hours, respectively.

Safety Profile

Poison by subcutaneous and intravenous routes. Experimental teratogenic effects. A powerful analgesic. When heated to decomposition it emits very toxic fumes of NOx and HCl. See also MORPHINE.

Drug interactions

Potentially hazardous interactions with other drugs Alcohol: can cause dose dumping with sustained release preparations. Analgesics: possible opioid withdrawal effects with buprenorphine and pentazocine. Antidepressants: possible CNS excitation or depression with MAOIs - avoid concomitant use and for 2 weeks after stopping MAOI; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclics. Antihistamines: increased sedative effects with sedating antihistamines. Antipsychotics: enhanced hypotensive and sedative effects. Dopaminergics: avoid with selegiline. Nalmefene: avoid concomitant use. Sodium oxybate: enhanced effect of sodium oxybate - avoid.

Metabolism

Hydromorphone undergoes extensive firstpass metabolism. It is extensively metabolised by glucuronidation in the liver and excreted in the urine mainly as conjugated hydromorphone, dihydroisomorphine, and dihydromorphine.

Check Digit Verification of cas no

The CAS Registry Mumber 71-68-1 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 7 and 1 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 71-68:
(4*7)+(3*1)+(2*6)+(1*8)=51
51 % 10 = 1
So 71-68-1 is a valid CAS Registry Number.
InChI:InChI=1/C17H19NO3.2ClH/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18;;/h2,4,10-11,16,19H,3,5-8H2,1H3;2*1H/t10-,11+,16-,17-;;/m0../s1

71-68-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name hydromorphone hydrochloride

1.2 Other means of identification

Product number -
Other names Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, hydrochloride, (5α)-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:71-68-1 SDS

71-68-1Relevant articles and documents

The intriguing effects of substituents in the N-phenethyl moiety of norhydromorphone: A bifunctional opioid from a set of "tail wags dog" experiments

Adler, Martin W.,Bergman, Jack,Chadderdon, Aaron M.,Crowley, Rachel Saylor,Geller, Ellen B.,Hanna, Ramsey D.,Hassan, Sergio A.,Herdman, Christine A.,Inan, Saadet,Irvin, Thomas C.,Jacobson, Arthur E.,Kaska, Sophia,Katz, Jonathan L.,Kopajtic, Theresa A.,Lee, Yong-Sok,Paronis, Carol A.,Prisinzano, Thomas E.,Rice, Kenner C.,Traynor, John R.,Wang, Meining,Withey, Sarah L.

, (2020/07/02)

(-)-N-Phenethyl analogs of optically pure N-norhydromorphone were synthesized and pharmacologically evaluated in several in vitro assays (opioid receptor binding, stimulation of [35S]GTPγS binding, forskolin-induced cAMP accumulation assay, and MOR-mediated β-arrestin recruitment assays). "Body"and "tail"interactions with opioid receptors (a subset of Portoghese's message-address theory) were used for molecular modeling and simulations, where the "address"can be considered the "body"of the hydromorphone molecule and the "message"delivered by the substituent (tail) on the aromatic ring of the N-phenethyl moiety. One compound, N-p-chlorophenethynorhydromorphone ((7aR,12bS)-3-(4-chlorophenethyl)-9-hydroxy-2,3,4,4a,5,6-hexahydro- 1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one, 2i), was found to have nanomolar binding affinity at MOR and DOR. It was a potent partial agonist at MOR and a full potent agonist at DOR with a δ/μ potency ratio of 1.2 in the ([35S]GTPγS) assay. Bifunctional opioids that interact with MOR and DOR, the latter as agonists or antagonists, have been reported to have fewer sideeffects than MOR agonists. The p-chlorophenethyl compound 2i was evaluated for its effect on respiration in both mice and squirrel monkeys. Compound 2i did not depress respiration (using normal air) in mice or squirrel monkeys. However, under conditions of hypercapnia (using air mixed with 5% CO2), respiration was depressed in squirrel monkeys.

Morphine alkone acid salt a refining technology of hydrogen (by machine translation)

-

Paragraph 0032-0034, (2017/03/17)

The invention aims to overcome the defects in the prior art, and provides a new refinement method of hydromorphone acid salt. The method comprises the following steps: a. adding hydromorphone and dilute acid into a reaction kettle, and dissolving by stirring at 30-60 DEG C; cooling to 15--5 DEG C, stirring to precipitate abundant solid, adding alcohol and ether, and stirring to crystallize for 0.5-3 hours; filtering, washing until the pH value of the filtrate is 6-7, and drying in a drying oven to obtain a hydromorphone acid salt crude product; b. adding purified water into a refinement decolorization tank, heating to 30-60 DEG C, adding the hydromorphone acid salt crude product, stirring until the hydromorphone acid salt crude product is completely dissolved, adding medicinal carbon, adding dilute acid, and decolorizing at the constant temperature of 30-60 DEG C for 10-30 minutes; filtering, washing the filter cake with purified water, merging the washing liquid and filtrate, distilling under reduced pressure, refrigerating at 5+/-5 DEG C to crystallize for more than 8 hours; and filtering, washing the filter cake with 95% ethanol, drying in a drying oven to obtain the hydromorphone acid salt.

Preparation of Saturated Ketone Morphinan Compounds by Catalytic Isomerization

-

Page/Page column 8, (2010/11/03)

The present invention provides processes for the preparation of saturated ketone morphinan compounds by catalytic isomerization. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an allyl-transition metal catalyst.